Mineralys Therapeutics, Inc.
MLYS
$14.89
$0.2751.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 28.93% | -8.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.17% | -14.14% | |||
| Operating Income | -5.17% | 14.14% | |||
| Income Before Tax | -2.52% | 13.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.52% | 13.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.52% | 13.76% | |||
| EBIT | -5.17% | 14.14% | |||
| EBITDA | -5.17% | 14.14% | |||
| EPS Basic | 16.73% | 18.95% | |||
| Normalized Basic EPS | 16.73% | 18.96% | |||
| EPS Diluted | 16.73% | 18.95% | |||
| Normalized Diluted EPS | 16.73% | 18.96% | |||
| Average Basic Shares Outstanding | 23.11% | 6.42% | |||
| Average Diluted Shares Outstanding | 23.11% | 6.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||